{"prompt": "['Appendix 6', 'Asymptomatic Decline in LVEF: Algorithm for Continuation and', 'Discontinuation of Study Treatment', 'LVEF drop from baseline', 'LVEF 50%', 'LVEF < 50%', 'LVEF drop', 'LVEF drop', 'LVEF drop', 'LVEF drop', '20 points', '> 20 points', '< 10 points', '10 points', 'Continue', 'Continue treatment and', 'Hold treatment and', 'treatment', 'repeat LVEF in 3 weeks', 'repeat LVEF in 3 weeks', 'LVEF drop confirmed', 'Not confirmed', '(LVEF drop 10 points', '(LVEF drop < 10 points', 'and LVEF < 50%)', 'or LVEF 50%)', 'Stop treatment', 'Resume treatment', 'LVEF = left ventricular ejection fraction', 'Patients must have an LVEF 55% measured by echocardiogram (ECHO) or multiple-gated', 'acquisition (MUGA) to be eligible for the study.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '125 / Protocol MO40628, Version 12']['Appendix 7', 'NYHA Functional Classification System for Heart Failure and LVSD', 'NCI CTCAE V4.0 Grading', 'NYHA Functional Classification System for Heart Failure', 'Class', 'Description', 'I', 'No limitation of physical activity. Ordinary physical activity does not cause undue', 'fatigue, palpitation, or dyspnea.', 'Il', 'Slight limitation of physical activity. Comfortable at rest, but ordinary physical', 'activity results in fatigue, palpitation, or dyspnea.', 'III', 'Marked limitation of physical activity. Comfortable at rest, but less than ordinary', 'activity causes fatigue, palpitation, or dyspnea.', 'IV', 'Inability to carry on any physical activity without discomfort. Symptoms of', 'cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is', 'increased.', 'LVSD NCI CTCAE V4 Grading', 'Investigations', 'Grade', '1', '2', '3', '4', '5', 'EF decreased', '-', 'Resting EF', 'Resting EF', 'Resting EF', '-', '[a]', '50% 40%;', '39% 20%;', '< 2050%', '10% 19%', '> 20% drop', 'drop from', 'from baseline', 'baseline', 'Cardiac Disorders', 'Grade', '1', '2', '3', '4', '5', 'Heart failure', 'Asymptomatic', 'Symptoms', 'Severe with', 'Life-', 'Death', '[b]', 'with laboratory', 'with mild to', 'symptoms at', 'threatening', '(e.g., BNP) or', 'moderate', 'rest or with', 'consequences;', 'cardiac', 'exertion', 'minimal', 'urgent', 'imaging', 'activity or', 'intervention', 'abnormalities', 'exertion;', 'indicated', 'intervention', '(e.g.,', 'indicated', 'continuous IV', 'therapy or', 'mechanical', 'hemodynamic', 'support)', 'BNP = B-natriuretic peptide; EF = ejection fraction; LVSD = left ventricular systolic dysfunction.', 'a. Definition: the percentage computed when the amount of blood ejected during a ventricular', 'contraction of the heart is compared to the amount that was present prior to the contraction.', 'b. Definition: a disorder characterized by the inability of the heart to pump blood at an adequate', 'volume to meet tissue metabolic requirements, or, the ability to do only at an elevation in the', 'filling pressure.', '  https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.p', 'https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf page 109)', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '126 / Protocol MO40628, Version 42']\n\n###\n\n", "completion": "END"}